Synapse - Michael Morris

Search Within

Michael Morris

Results (112)

Automated bone scan index to optimize prostate cancer working group radiographic progression criteria for men with metastatic castration-resistant prostate cancer

Journal Article

Anand, A.; Heller, G.; Fox, J.; Danila, D. C.; Bjartell, A.; Edenbrandt, L.; Larson, S. M.; Scher, H. I.; Morris, M. J.
Clinical Genitourinary Cancer (2022)

Fulltext@MSK | Save

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Use of bone modifying agents for metastatic castrate-resistant prostate cancer

Meeting Abstract

Mitchell, A. P.; Mishra Meza, A.; Farooki, A.; Panageas, K.; Bach, P. B.; Lipitz-Snyderman, A.; Morris, M. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Real-world use of bone-modifying agents in metastatic castration-sensitive prostate cancer

Journal Article

Mitchell, A. P.; Mishra Meza, A.; Panageas, K. S.; Lipitz-Snyderman, A.; Bach, P. B.; Morris, M. J.
JNCI: Journal of the National Cancer Institute (2022)

Fulltext@MSK | Save

Correlation between imaging-based intermediate endpoints and overall survival in men with metastatic castration-resistant prostate cancer: Analysis of 28 randomized trials using the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria in 16,511 patients

Journal Article

Woo, S.; Suh, C. H.; Wibmer, A. G.; Becker, A. S.; Teo, M. Y.; Gönen, M.; Hricak, H.; Scher, H. I.; Morris, M. J.; Vargas, H. A.
Clinical Genitourinary Cancer (2022)

Fulltext@MSK | Save

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Journal Article

Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
Cell (2022)

Fulltext@MSK | Save

Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors

Journal Article

Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Characterization of findings on prostate cancer tumor sequencing that should prompt consideration for germline testing

Meeting Abstract

Truong, H.; Breen, K.; Kemel, Y.; Lenis, A. T.; Reisz, P.; Benfante, N.; Ehdaie, B.; Touijer, K. A.; Laudone, V. P.; Scardino, P. T.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Quantification of metastatic prostate cancer whole-body tumor burden with (18)F-FDG PET parameters and associations with overall survival after first-line abiraterone or enzalutamide: A single-center retrospective cohort study

Journal Article

Wibmer, A. G.; Morris, M. J.; Gonen, M.; Zheng, J.; Hricak, H.; Larson, S.; Scher, H. I.; Vargas, H. A.
Journal of Nuclear Medicine (2021)

Fulltext@MSK | Save

Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy

Journal Article

Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
European Urology Open Science (2021)

Fulltext@MSK | Save